Department of Radiology, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy.
AJR Am J Roentgenol. 2012 Apr;198(4):809-16. doi: 10.2214/AJR.11.7118.
Gadobutrol is an extracellular macrocyclic gadolinium chelate recently introduced in MRI, and it has already been used for cardiac late enhancement imaging; however, until now it has never been compared with gadopentetate dimeglumine. The purpose of our study was to compare 0.1 mmol/kg gadobutrol to 0.2 mmol/kg gadopentetate dimeglumine for the detection of myocardial late enhancement in the same group of patients.
This was an exploratory single-blind parallel group study comparing gadobutrol (0.1 mmol/kg) to gadopentetate dimeglumine (0.2 mmol/kg) in 20 adult patients scheduled for cardiac late enhancement MRI with gadopentetate dimeglumine and whose MR images showed late enhancement. MR images were acquired at 10, 15, and 20 minutes after peripheral injection of gadobutrol by using a 3D turbo field echo inversion recovery T1-weighted sequence. Volume and percentage of late enhancement, number of involved segments, late enhancement localization and pattern, and late enhancement signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were compared between contrast agents.
Late enhancement was not significantly different with gadobutrol and gadopentetate dimeglumine both in terms of total volume of myocardium (mean ± SD, 37.8 ± 56.1 and 35.1 ± 46.7 cm(3), respectively; p = 0.33) and percentage of myocardial wall involvement (22.5% ± 19.1% and 22.0% ± 17.2%, respectively; p = 0.67). The number of segments involved was not different (138 with gadobutrol vs 134 with gadopentetate dimeglumine). Furthermore, SNR and CNR were not different (gadopentetate dimeglumine, 123.8 ± 82.9 and gadobutrol, 117.2 ± 88.6, p = 0.58 and gadopentetate dimeglumine, 96.2 ± 68.9 and gadobutrol, 88.4 ± 72.9, p = 0.53, respectively).
A single dose of gadobutrol seems to be as effective as a double dose of gadopentetate dimeglumine for the detection of late enhancement.
钆布醇是一种新型的细胞外大环型顺磁对比剂，已用于心脏磁共振延迟强化成像，但尚未与马根维显进行对比。本研究旨在对比 0.1mmol/kg 剂量的钆布醇与 0.2mmol/kg 剂量的马根维显在同一组患者中的心脏磁共振延迟强化检测效果。
这是一项单盲、平行组比较研究，纳入了 20 例行马根维显心脏磁共振延迟强化成像的成年患者，这些患者的磁共振图像存在延迟强化。外周静脉注射对比剂后 10、15 和 20 分钟，使用三维涡轮场回波反转恢复 T1 加权序列采集图像。比较两种对比剂的延迟强化总体容积、心肌强化百分比、累及节段数、延迟强化部位及强化模式、延迟强化信噪比（signal-to-noise ratio，SNR）和对比噪声比（contrast-to-noise ratio，CNR）。
钆布醇与马根维显在心肌总体强化容积[（37.8 ± 56.1）cm3 比（35.1 ± 46.7）cm3；p = 0.33]和心肌强化百分比[（22.5% ± 19.1%）比（22.0% ± 17.2%）；p = 0.67]方面差异均无统计学意义。累及节段数也无差异[分别为 138 节段和 134 节段]。此外，SNR 和 CNR 也无差异[分别为 123.8 ± 82.9 和 117.2 ± 88.6，p = 0.58；96.2 ± 68.9 和 88.4 ± 72.9，p = 0.53]。
单次剂量的钆布醇与双倍剂量的马根维显在检测心脏磁共振延迟强化方面具有同等效果。
